Skip to Content

Weekly Drug News Round-Up: November 29, 2017

Kaléo’s Auvi-Q (epinephrine) Auto-Injector Approved for Small Children

The needle length in Auvi-Q 0.1 mg was specifically designed for use with infants and small children Read More...

A smaller patient population can now use Auvi-Q. The U.S. Food and Drug Administration (FDA) has approved Kaléo's Auvi-Q (epinephrine) 0.1 mg Auto-Injector for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) who are at risk for or have a history of serious allergic reactions. The new 0.1 mg-dose is a lower dose than the currently FDA-approved 0.15 mg and 0.3 mg epinephrine auto-injectors. The Auvi-Q 0.1 mg Auto-injector is projected to be available for patients in the first half of 2018.

Genentech’s Gazyva Cleared for Advanced Follicular Lymphoma

Follicular lymphoma, the most common slow-growing form of non-Hodgkin’s lymphoma (NHL), is incurable Read More...

The FDA has approved Genentech's  Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). Gazyva is a CD20-directed cytolytic antibody also indicated for the combination treatment of patients with chronic lymphocytic leukemia. In the the Phase III GALLIUM study, Gazyva showed superior progression-free survival (PFS) when compared to a Rituxan (rituximab)-based regimen as initial therapy, and significantly reduced the risk of disease worsening or death by 28 percent. Common side effects include infusion reactions, low white blood cell count, upper respiratory tract infection, and cough.

Drug Interaction Facts for Your Drug Safety: Poll

Use of multiple pharmacies and doctors by a patient may play a role in this lack of communication Read More...

When was the last you time you had a discussion about possible drug interactions with your doctor? New data published by the University of Michigan Medical School reveals that out of nearly 1,700 adults ages 50 to 80, only about 1 in 3 who took at least one prescription drug had talked to a health care professional about possible drug interactions in the past two years. Plus, only 36 percent said their pharmacist knew all their meds. Always review your prescription, over-the-counter, and herbal medications for possible drug interactions with a healthcare provider. View the article Top 9 Ways to Prevent a Deadly Drug Interaction to learn more.

Seasonal Allergies: What’s the Top Recommendation?

Tree, grass, and weed pollen, plus mold spores can lead to year-round allergies Read More...

Allergies don’t just happen in the spring. In fact, for many, seasonal allergies (hay fever) can be present year-round. Two allergy expert groups just released new guidelines on top ways to suppress those bothersome symptoms. For most people 12 years and older, over-the-counter (OTC) nasal steroid sprays, like Nasacort, Nasonex, Flonase and Rhinocort (or generics), are the way to go initially. Prescription brands include Beconase, Qnasl and Veramyst. These are very effective and have fewer side effects than some oral medications. If these don't work, oral antihistamines, nasal antihistamines and leukotriene blockers like Singular or Accolate, or even allergy shots may also lessen symptoms.

Steroid Injections and Bone Changes in Arthritic Hips: Study

Early research suggests bone deterioration in the hip many occur more rapidly with steroid injections Read More…

Steroid injections into painful joints, like knees, shoulders, and hips, are a common practice for osteoarthritis. While they offer pain relief, it's only a temporary fix. New, preliminary research available this week suggests that steroid injections to arthritic hips may exacerbate bone trouble. Investigators followed patients who received steroid hip injections, and those that didn’t, and found higher rates of bone death and collapse 3 to 9 months later in those who had the hip injections. Ultimately, researchers hypothesize that patients go on to use their weight-bearing joints more strenuously after pain-relieving steroid injections, exacerbating their osteoarthritis. View the Osteoarthritis Slideshow to learn more.